Table 3.
Summary of antimicrobial susceptibility pattern observed for novel lactic acid bacteria (LAB) strains.
| Antimicrobial | Antimicrobial | Abbreviation | Susceptibility | No. of non-susceptible | |
|---|---|---|---|---|---|
| Class | agent | (%)a | isolates classified as |
||
| Intermediate | Resistant | ||||
| Penicillin | Ampicilin | AMP | 100.00 (28/28) | 0 | 0 |
| Penicillin | PEN | 100.00 (28/28) | 0 | 0 | |
| Oxazolidinones | Linezolid | LZD | 100.00 (28/28) | 0 | 0 |
| Rifamycin | Rifampicin | RIF | 85.71 (24/28) | 3 | 1 |
| Folate pathway inhibitor | Tmp/Sxt | SXT | 78.57 (22/28) | 0 | 6 |
| Glycopeptide | Vancomycin | VAN | 75.00 (21/28) | 0 | 7 |
| Aminoglycoside | Gentamicin | GEN | 71.43 (20/28) | 7 | 1 |
| Lincosamide | Clindamycin | CLI | 67.86 (19/28) | 0 | 9 |
| Spectrogramin | Synercid | SYN | 67.86 (19/28) | 2 | 7 |
| Tetracycline | Tetracycline | TET | 64.29 (18/28) | 4 | 6 |
| Lipopeptide | Daptomycin | DAP | 53.57 (15/28) | 13 | 0 |
| Fluoroquinolone | Levofloxacin | LVX | 39.29 (11/28) | 0 | 17 |
| Macrolide | Erythromycin | ERY | 28.57 (8/28) | 20 | 0 |
aMinimum Inhibitory Concentration (MIC) breakpoints were interpreted based on the Clinical and Laboratory Standards Institute (Clinical and Laboratory Standards Institute, 2017), where isolates were classified into categories of (i) susceptible or (ii) non-susceptible, which includes both resistant and intermediately resistant.